Is Mankind Pharma overvalued or undervalued?

As of 8 August 2025, Mankind Pharma's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. However, the company remains overvalued based on its key financial ratios, including a PE Ratio of 53.68, an EV to EBITDA of 33.72, and a Price to Book Value of 7.11. These figures suggest that the stock is trading at a premium compared to its earnings and book value.
In comparison to its peers, Mankind Pharma's PE Ratio is significantly higher than Sun Pharma's 33.19 and Cipla's more attractive 22.23, highlighting its overvaluation in the market. Additionally, the company's recent performance shows a year-to-date decline of 14.28%, contrasting with a modest 2.20% gain in the Sensex, further reinforcing the notion that Mankind Pharma is overvalued at its current price of 2465.90.